

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (03-00)

Approved for use through 12/31/2002. CMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number

10/077,719

Filing Date

02/15/2002

First Named Inventor

RODRIGUEZ

Group Art Unit

1614

Examiner Name

PAK

Total Number of Pages in This Submission 14

Attorney Docket Number

PS 00-07-01

ENCLOSURES (check all that apply)☐ Fee Transmittal Form☐ Fee Attached☒ Amendment / Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Response to Missing Parts/Incomplete Application☐ Response to Missing Parts under 37 CFR 1.52 or 1.53☐ Assignment Papers (for an Application)☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a Provisional Application☐ Power of Attorney, Revocation Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) _____☐ After Allowance Communication to Group☐ Appeal Communication to Board of Appeals and Interferences☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☐ Other Enclosure(s) (please identify below):

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENTFirm
or
Individual name

Donald A. Bergquist, 31,589

Signature

Donald A Bergquist

Date

01/21/2003

CERTIFICATE OF MAILINGI hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

Typed or printed name

Signature

Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

AMENDMENT

In the claims:

Amend claim 1 to read:

1. [AMENDED] A method for the treatment and prophylaxis of conditions of aging associated with a decreased presence of cell-specific carbonic anhydrase enzymes in the brain, said conditions comprising conditions associated with chronic neurodegenerative conditions including dementia and Alzheimer's disease. which method comprises the administering over an extended period of time in the range of six months to five years, of a pharmaceutically effective, non-toxic amount of a non-enzyme compound that increases the presence of said cell-specific carbonic anhydrase enzymes in the brain.

Delete claim 2.

Delete claim 3.

Delete claim 4.

Amend claim 10 to read:

10. [AMENDED] The method of claim 5 wherein said compound is selected from the list composed of: [zinc; sex hormones, androgens; non-steroidal anti-inflammatory drugs, including indomethacin; 1,25-dihydroxyvitamin D3; phorbol myristate acetate; cysteamine; and sulfonylamido derivatives of histamine] sulfonylamido derivatives of histamine; 1,25-dihydroxyvitamin D3; phorbol myristate acetate; non-steroidal anti-inflammatory drugs, including indomethacin; sex hormones; androgens; zinc; and cysteamine.

Delete claim 11.